Nothing Special   »   [go: up one dir, main page]

PL444462A1 - Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer - Google Patents

Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer

Info

Publication number
PL444462A1
PL444462A1 PL444462A PL44446223A PL444462A1 PL 444462 A1 PL444462 A1 PL 444462A1 PL 444462 A PL444462 A PL 444462A PL 44446223 A PL44446223 A PL 44446223A PL 444462 A1 PL444462 A1 PL 444462A1
Authority
PL
Poland
Prior art keywords
assessing
anticancer drugs
breast cancer
cancer cells
vivo diagnosis
Prior art date
Application number
PL444462A
Other languages
Polish (pl)
Inventor
Dariusz PAWLAK
Anna TANKIEWICZ-KWEDLO
Krystyna PAWLAK
Bogumiła Czartoryska-Arłukowicz
Leszek KOZŁOWSKI
Tomasz ŁOBACZ
Mariusz KODA
Original Assignee
Uniwersytet Medyczny W Białymstoku
Białostockie Centrum Onkologii Im. M. Skłodowskiej-Curie W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku, Białostockie Centrum Onkologii Im. M. Skłodowskiej-Curie W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL444462A priority Critical patent/PL444462A1/en
Priority to PCT/IB2024/053727 priority patent/WO2024218665A1/en
Publication of PL444462A1 publication Critical patent/PL444462A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem wynalazku jest sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe przed włączeniem ich do terapii konkretnego pacjenta onkologicznego, określany przez twórców wynalazku jako Oncochem-Test. Kolejnym przedmiotem wynalazku jest sposób diagnostyki ex vivo nowotworu piersi.The subject of the invention is a method for assessing the chemosensitivity of cancer cells in vitro to anticancer drugs before including them in the therapy of a specific oncological patient, referred to by the inventors as Oncochem-Test. Another subject of the invention is a method for ex vivo diagnostics of breast cancer.

PL444462A 2023-04-18 2023-04-18 Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer PL444462A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL444462A PL444462A1 (en) 2023-04-18 2023-04-18 Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer
PCT/IB2024/053727 WO2024218665A1 (en) 2023-04-18 2024-04-17 Method for in vitro assessment of the chemosensitivity of neoplastic cells to antineoplastic drugs and method for ex vivo diagnostics of breast neoplasm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444462A PL444462A1 (en) 2023-04-18 2023-04-18 Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
PL444462A1 true PL444462A1 (en) 2024-10-21

Family

ID=91954018

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444462A PL444462A1 (en) 2023-04-18 2023-04-18 Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer

Country Status (2)

Country Link
PL (1) PL444462A1 (en)
WO (1) WO2024218665A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050962A1 (en) * 2011-10-04 2013-04-11 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
CN110373445A (en) * 2019-06-21 2019-10-25 南通大学 A kind of preparation method and application method of the quick drug effect test kit of anti-tumor drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080066663A (en) * 2005-09-21 2008-07-16 씨씨씨 디아그노스틱스 엘엘씨 Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy(pac)
JP2020516243A (en) * 2017-04-05 2020-06-11 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． Ex vivo culture system and method of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050962A1 (en) * 2011-10-04 2013-04-11 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
CN110373445A (en) * 2019-06-21 2019-10-25 南通大学 A kind of preparation method and application method of the quick drug effect test kit of anti-tumor drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PELIZZARI, G. ET AL.: "Cancers 2019, 11, 1243, doi: 10.3390/cancers11091243", "LACTATE DEHYDROGENASE (LDH) RESPONSE TO FIRST-LINE TREATMENT PREDICTS SURVIVAL IN METASTATIC BREAST CANCER: FIRST CLUSES FOR A COST-EFFECTIVE AND DYNAMIC BIOMARKER" *

Also Published As

Publication number Publication date
WO2024218665A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
AR076197A1 (en) TREATMENT REGIME USED BY NERATINIB FOR BREAST CANCER
EA201290138A1 (en) DERIVATIVES OF PYRAZOLES AS MODULATORS OF THE CALCIUM CHANNELS ACTIVATED BY CALCIUM RELIEF
BR112014025269A2 (en) Method for cancer metastasis prognosis and treatment
EA201290139A1 (en) MODULATORS OF THE CALCIUM CHANNEL ACTIVATED BY CALCIUM RELIEF PRESENTATION OF PYRAZOL DERIVATIVES AND METHODS OF TREATMENT OF LIGHT-TERM CELL LUNG CANCER
BR112016007864A2 (en) Method for cancer prognosis and metastasis treatment
AR083357A1 (en) METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER MASS CANCER METASTASIS
UA124238U (en) METHOD OF TREATMENT OF BREAST CANCER
Ramondetta What is the appropriate approach to treating women with incurable cervical cancer?
BR112014004336A2 (en) system and method for estimating the amount of interest of a dynamic artery / tissue / vein system
EA201792447A1 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSTICS AND TREATMENT OF DISEASES IN PATIENTS WITH HIGH LEVELS OF CXCL9 AND OTHER BIOMARKERS
AR115566A1 (en) COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF CANCER
BR112015031950A2 (en) Methods for Ovarian Cancer Treatment
PL444462A1 (en) Method for assessing the in vitro chemosensitivity of cancer cells to anticancer drugs and method for ex vivo diagnosis of breast cancer
BR112014018374A8 (en) METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH CANCER, KIT, ANTIBODY, METHOD FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITION
MX2021009247A (en) Methods, systems, and kits for treating inflammatory disease targeting il18r1.
ES2570609T3 (en) Method for testing aminoacylase 1 for in vitro diagnosis of colorectal cancer
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
Falasca et al. Cannabinoids and Cancer
AR089833A1 (en) PREDICTIVE BIOMARCATOR FOR THE TREATMENT OF CANCER WITH INCREASED ADCC ANTIBODIES
RU2013140122A (en) DIAGNOSTIC METHOD OF BREAST CANCER
WO2022130433A3 (en) Method for in vitro diagnosis of mucositis in cancer patients undergoing antitumor therapy
AWARDS HIGHLIGHTS OF THE NCCN 2022 ANNUAL CONFERENCE
PT117573A (en) 3D BIOPRINTING OF HUMAN MORPHOMETRIC TUMOR TISSUE DUCTS COMPRISING A HYDROGEL MATRIX, PRODUCTION AND USE OF THEM
Li et al. Comparison of survival outcomes following radiotherapy versus radical hysterectomy in patients with stage IIA cervical squamous cell carcinoma.
Crown et al. Extreme Oncoplastic Breast Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use?